SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alcon Inc. NYSE:ALC | $35.61B | $74.12 | Undervalued | 38.7 | +0.28% |
Glaukos Corporation NYSE:GKOS | $14.55B | $245.72 | Not rated | -39.0 | +141.56% |
Bausch + Lomb Corporation NYSE:BLCO | $7.54B | $21.09 | Overvalued | -24.2 | +43.30% |
Ocular Therapeutix, Inc. NASDAQ:OCUL | $1.37B | $6.21 | Not rated | -7.3 | -50.91% |
STAAR Surgical Company NASDAQ:STAA | $1.32B | $26.39 | Not rated | -68.3 | -4.16% |
Sight Sciences, Inc. NASDAQ:SGHT | $601.92M | $10.83 | Not rated | -7.5 | +55.41% |
Oculis Holding AG NASDAQ:OCS | $471.63M | $7.64 | Not rated | -5.5 | -61.65% |
RxSight, Inc. NASDAQ:RXST | $223.06M | $5.32 | Not rated | -4.1 | -47.26% |
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | $25.66M | $0.31 | Not rated | -4.2 | -79.06% |
Continue the stock analysis
Jump to another research area for this company.